165 related articles for article (PubMed ID: 38388873)
21. Alpelisib: First Global Approval.
Markham A
Drugs; 2019 Jul; 79(11):1249-1253. PubMed ID: 31256368
[TBL] [Abstract][Full Text] [Related]
22. Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
Crabb SJ; Griffiths G; Dunkley D; Downs N; Ellis M; Radford M; Light M; Northey J; Whitehead A; Wilding S; Birtle AJ; Khoo V; Jones RJ
Eur Urol; 2022 Nov; 82(5):512-515. PubMed ID: 35688662
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
Ozaki Y; Aoyama Y; Masuda J; Inagaki L; Kawai S; Shibayama T; Maeda T; Kurata M; Yoshida K; Saeki S; Hosonaga M; Fukada I; Hara F; Kobayashi T; Kobayashi K; Miyake S; Takano T; Ueno T; Ohno S
BMC Cancer; 2022 Jan; 22(1):36. PubMed ID: 34983437
[TBL] [Abstract][Full Text] [Related]
25. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
26. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
[TBL] [Abstract][Full Text] [Related]
27. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Watanabe K; Niikura N; Kikawa Y; Oba M; Kobayashi K; Tada H; Ozaki S; Toh U; Yamamoto Y; Tsuneizumi M; Okuno T; Iwakuma N; Takeshita T; Iwamoto T; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2023 Jun; 199(2):253-263. PubMed ID: 37000345
[TBL] [Abstract][Full Text] [Related]
28. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Nagaraj G; Ma CX
Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
[TBL] [Abstract][Full Text] [Related]
29. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).
Burstein HJ; Cirrincione CT; Barry WT; Chew HK; Tolaney SM; Lake DE; Ma C; Blackwell KL; Winer EP; Hudis CA
J Clin Oncol; 2014 Dec; 32(35):3959-66. PubMed ID: 25348000
[TBL] [Abstract][Full Text] [Related]
30. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T; Niikura N; Watanabe K; Takeshita T; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2024 Jan; 203(2):225-234. PubMed ID: 37875670
[TBL] [Abstract][Full Text] [Related]
31. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
32. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
33. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
O'Shaughnessy J; Thaddeus Beck J; Royce M
Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
[TBL] [Abstract][Full Text] [Related]
34. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
35. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
36. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
37. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
39. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657
[TBL] [Abstract][Full Text] [Related]
40. Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review.
Li J; Wang Z; Shao Z
Cancer Med; 2019 May; 8(5):1943-1957. PubMed ID: 31004402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
